Structure–activity relationship study of EphB3 receptor tyrosine kinase inhibitors by Qiao, Lixin et al.
Structure-activity relationship study of EphB3 receptor tyrosine
kinase inhibitors
Lixin Qiaoa, Sungwoon Choia, April Casea, Thomas G. Gainera,b, Kathleen Seyba, Marcie A.
Glicksmana, Donald C. Lob, Ross L. Steina, and Gregory D. Cuny*,a
aLaboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham &
Women’s Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139,
USA
bCenter for Drug Discovery and Department of Neurobiology, Duke University Medical Center, 4321
Medical Park Drive, Suite 200, Durham, North Carolina 27704, USA
Abstract
A structure-activity relationship study for a 2-chloroanilide derivative of pyrazolo[1,5-a]pyridine
revealed that increased EphB3 kinase inhibitory activity could be accomplished by retaining the 2-
chloroanilide and introducing a phenyl or small electron donating substituents to the 5-position of
the pyrazolo[1,5-a]pyridine. In addition, replacement of the pyrazolo[1,5-a]pyridine with imidazo
[1,2-a]pyridine was well tolerated and resulted in enhanced mouse liver microsome stability. The
structure-activity relationship for EphB3 inhibition of both heterocyclic series was similar. Kinase
inhibitory activity was also demonstrated for representative analogs in cell culture. An analog (32,
LDN-211904) was also profiled for inhibitory activity against a panel of two hundred and eighty
eight kinases and found to be quite selective for tyrosine kinases. Overall, these studies provide useful
molecular probes for examining the in vitro, cellular and potentially in vivo kinase-dependent
function of EphB3 receptor.
Erythropoietin-producing hepatocellular carcinoma (Eph) receptors are highly conserved
transmembrane proteins composed of multiple domains that participate in an array of complex
cell signaling pathways. Sixteen Eph receptors have been identified in vertebrates. They can
be divided into two major classes (EphA and EphB) based on sequence similarity in the
extracellular domain and binding characteristics. Mammals, including humans, have fourteen
Eph receptors (EphA1 – EphA8, EphA10, EphB1 – EphB4 and EphB6).1
The Eph receptors interact with cell surface ligands called Eph receptor interacting proteins
(ephrins).2 Currently, nine ephrins are known and are divided into two major classes (ephrin
A1 – 6 and ephrin B1 – 3). Humans have all but ephrin A6. Following binding of the Eph
receptors to the ephrin ligands, which requires cell-cell interactions, propagation of signaling
occurs bi-directionally into both the Eph receptor and the ephrin presenting cells.3 The
signaling events resulting from these interactions are important in both neural development4
and during adulthood. For example, the Eph receptors together with ephrins participate in axon
guidance by providing repulsive cues during axonal neurogenesis.
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The EphB3 receptor subtype is expressed during embryonic development and in discrete areas
of the adult brain, including the cerebellum and hippocampus. It co-localizes to brain regions
with high levels of ephrin B ligand expression.5 EphB3 receptor expression also increases
following central nervous system injury. However, it remains unclear if EphB3 is inhibitory
to axonal regeneration or beneficial for axonal repair. For example, following adult optic nerve
injury, EphB3 receptor appears and coincides with retinal ganglion cell axon sprouting and
remodeling.6 However, after spinal cord injury EphB3 expression increases and appears to
contribute to restricted axonal regeneration and sprouting.7 Increased EphB3 receptor
expression has also been documented in pancreatic cancer cell lines,8 squamous cell carcinoma,
9a and rhabdomyosarcoma.9b
In addition to ligand binding domains, the Eph receptors have an intracellular tyrosine kinase
domain, although EphA10 and EphB6 lack essential amino acid residues to enable catalysis.
The Eph receptor’s kinase activity is required for some, but not all, of the signal transduction
pathways involving Eph receptors.10
Engagement of the ephrin ligands with the Eph receptors initially results in receptor
dimerization followed by autophosphorylation of tyrosine residues in the juxtamembrane
region of the receptor, which is located between the transmembrane and the kinase domains.
These phosphorylation events result in kinase activation by dissociation of the juxtamembrane
segment from the kinase domain.11 Once fully active, the kinase domain then can bind and
phosphorylate intracellular adaptor molecules perpetuating signaling.
Ligands that target different binding components of Eph receptors could serve as useful
molecular probes to help elucidate the cellular biology and in vivo physiology of Eph receptors.
12 These ligands could also be used to selectively modulate Eph receptor’s kinase-dependent
and independent functions.13 Utilizing a recently developed high throughput screen (HTS) for
EphB3 kinase activity,14 the pyrazolo[1,5-a]pyridine derivative 1 was discovered as a
moderately potent inhibitor (IC50 ~ 1 µM). Herein, we describe the results of a structure-activity
relationship study to optimize EphB3 kinase inhibition and to increase mouse liver microsome
stability. In addition, kinase inhibitory activity is also demonstrated in cell culture and a select
analog is profiled against a broad panel of kinases.
The synthesis of many pyrazolo[1,5-a]pyridine derivatives was accomplished according to
Scheme 1 (Method A). Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 2, was converted to the
corresponding acyl chloride and then treated with amines to give 3. Derivatives incorporating
other heterocycles in place of the pyrazolo[1,5-a]pyridine were prepared in a similar manner,
unless otherwise noted. The amide could be reduced with LiAlH4 to give amine 4.
Carboxylic acid 2 was also allowed to react with (PhO)2P(O)N3 to generated the corresponding
acyl azide, which upon heating in the presence of benzyl alcohol underwent a Curtius
rearrangement followed by alcohol addition to the intermediate isocyanate to produce 5
(Scheme 2, Method B).15 Deprotection of the benzyl carbamate in the presence of hydrogen
(1 atm) and 10% Pd/C yielded amine 6, which upon treatment of 2-chlorobenzoyl chloride
gave 7.
The synthesis of substituted pyrazolo[1,5-a]pyridine and derivatives that incorporate
additional nitrogen atoms into the pyrazolo[1,5-a]pyridine is illustrated in Scheme 3 (Method
C). Heterocycles 8 were converted to the N-amino derivatives 9 with mesitylSO3NH2.16
Cycloaddition with methyl propiolate in the presence of potassium carbonate gave 10 in low
yield.17 Hydrolysis of the esters yielded 11. Conversion of the carboxylic acids to the
corresponding acyl chlorides with thionyl chloride followed by treatment with 2-chloroaniline
in pyridine gave 12.
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The synthesis of 5-amino substituted pyrazolo[1,5-a]pyridine derivatives is outlined in Scheme
4 (Method D). 4-Chloropyridinium hydrochloride, 13, was treated with an amine to generate
14, via a nucleophilic aromatic substitution. Conversion of 14 to the N-aminopyridine 15 with
2,4-(NO2)2PhONH2 followed by cycloaddition with N-(2-chlorophenyl)-2-propynamide18
produced 16.
The synthesis of imidazo[1,2-a]pyridine derivatives was accomplished according to Scheme
5 (Method E). 2-Amino-5-bromopyridine, 17, was coupled with phenyl boronic acid to give
18. 5-Bromo-2-nitropyridine, 19, was treated with piperidine to give 20, which was
subsequently hydrogenated in the presence of 10% Pd/C to yield 21. The 2-aminopyridines
18 or 21 were heated at reflux in toluene with N,N-dimethylformamide dimethyl acetal (DMF-
DMA) and then treated with 2-bromo-N-arylacetamides (prepared by coupling anilines with
2-bromoacetyl chloride) to give 22.19 β-Ketoamide 23 was chlorinated with sulfuryl chloride
yielding 24, which was used without purification. Heating 24 in the presence of 17 and sodium
bicarbonate gave the 2-methyl imidazo[1,2-a]pyridine derivative 25.
The synthesis of several other 5-substituted imidazo[1,2-a]pyridine derivatives was
accomplished according to the method outlined in Scheme 6 (Method F). A Pd-mediated
coupling of boronic ester 26 with 17 followed by hydrogenation of the alkene yielded 27.
Amine 17 was also converted to intermediate 28,20 which was not isolated, but subjected to
halogen metal exchange with n-BuLi followed by addition of N-Boc-4-piperidone to give 29
after an acidic work-up. Both 27 and 29 were converted to 30 and 31, respectively, utilizing
the procedure described in Method E.19 Finally, removal of the carbamate protecting groups
from 30 and 31 with 30% TFA in dichloromethane produced amines 32 and 33, respectively.
Evaluation of EphB3 kinase inhibitory activity for the various compounds was accessed by
measuring 33P incorporation into the BTK-peptide (Cell Signaling) in the presence of varying
test compound concentrations. Progress curves for production of phospho-BTK were linear
for at least 30 min, allowing the calculation of observed velocities. IC50 values were then
determined using a two parameter fit.14
The 2-chloro substituent on the aniline ring was necessary for kinase inhibitory activity (Table
1). Removal of this group, replacing it with other electron withdrawing or donating substituents,
or transposing it to the 3- or 4-positions were all detrimental. In addition, methylation of the
amide (43), insertion of a methylene to give a benzylamine derivative (44), inverting the amide
functional group (7) or reduction of the amide to an amine (45) all resulted in diminished EphB3
kinase inhibitory activity.
Interestingly, addition of a methyl substituent to the 4-, 6-, or 7-positions of the pyrazolo[1,5-
a]pyridine was also detrimental. However, placement of the methyl substituent in the 5-position
(47) resulted in increased activity. Similarly, introduction of a chlorine to the 5-position (51)
was also tolerated, but not at the 4- or 6-positions. Based on these results, other substituents
were examined at the 5-position of the pyrazolo[1,5-a]pyridine. Introduction of a phenyl
(54), dimethylamino (55) or N-piperidinyl (58) further increased activity resulting in IC50
values < 100 nM. However, a larger benzyloxy (59) substituent was not tolerated at the 5-
position.
Various replacements of the pyrazolo[1,5-a]pyridine were next examined (Table 2). Most of
the heterocycles, including indoles (60 and 61), a quinoline (62), a 1,2-benzisoxazole (63), an
indazole (64) and pyrazolo[1,5-a]pyridines incorporating an additional nitrogen atom into the
heterocycle (65 – 68) did not inhibit EphB3 kinase activity at concentrations < 15 µM.
However, replacement of the pyrazolo[1,5-a]pyridine with an imidazo[1,2-a]pyridine (69)
retained activity with an IC50 = 0.46 µM.
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Several of the SAR findings established for the pyrazolo[1,5-a]pyridine derivatives were next
examined for the imidazo[1,2-a]pyridine series (Table 3). Introduction of substituents, such as
bromo (25), phenyl (70) and N-piperidinyl (71), at the 5-position again resulted in a significant
increase in EphB3 inhibitory activity with IC50 values < 100 nM, whereas replacing the 2-
chloroanilide with a 2-methoxyanilide (72) or introduction of a methyl substituent at the 2-
position of the imidazo[1,2-a]pyridine (73) abolished inhibitory activity. The 4-piperidinyl
analog (32) retained significant EphB3 inhibitory activity, while also offering greater aqueous
solubility due to the presence of a basic amine. However, the inhibitory activity was eroded
with further introduction of a hydroxyl group onto the 4-piperidinyl ring (33).
Next, several derivatives were assessed for in vitro metabolic stability in pooled mouse liver
microsomes.14, 21 The results of these studies are shown in Table 4. Both pyrazolo[1,5-a]
pyridine and imidazo[1,2-a]pyridine analogs either without substitution or with an amino group
attached through a N-C bond at the 5-position of the heterocycle (1, 58, 69 and 71) demonstrated
poor stability (t1/2 ≤ 20 min). However, introduction of a substituent through a C-C bond at
the 5-position (54 and 70) resulted in increased stability, with 32 demonstrating the best
stability with a t1/2 of 348 min and a CLint of 4 µL/min/mg protein.
A subset of analogs was also evaluated for inhibition of EphB3 receptor autophosphorylation
in HEK293 cells following stimulation with ephrinB3 (Figure 2).14 Several compounds (34,
35, 37, 61, and 72) that were inactive or weakly active in the in vitro biochemical kinase assay
were found to be inactive or weakly active in this cell-based assay. In contrast, derivatives (1,
32, 33, 58, and 71) that were active in the biochemical assay again demonstrated potent activity
in cells.
Finally, 32 was profiled for functional inhibitory activity against a panel of two hundred and
eighty eight kinases at 5 µM.22 The results demonstrated that this compound was quite selective
for tyrosine kinases (Table S1 and Figure S1).14 The only noted exceptions were the three
serine/threonine kinases p38α, p38β and Qik. In addition, the compound only showed moderate
selectivity among the tyrosine kinases and little selectivity verses other EphA and EphB
subtypes, except for EphA6 and EphA7.
In conclusion, a structure-activity relationship study of the pyrazolo[1,5-a]pyridine 1,
identified as an EphB3 kinase inhibitor utilizing a recently developed HTS assay, revealed that
increased inhibitory activity could be accomplished by retaining the 2-chloroanilide and
introducing a phenyl or small electron donating substituent to the 5-position of the pyrazolo
[1,5-a]pyridine. In addition, replacement of the pyrazolo[1,5-a]pyridine with an imidazo[1,2-
a]pyridine was well tolerated and the resulting structure-activity relationship of both
heterocyclic series was similar. However, the imidazo[1,2-a]pyridines offered enhanced in
vitro metabolic stability as assessed in mouse liver microsomes. In particular, 32
(LDN-211904) was a potent EphB3 inhibitor, displaying excellent liver microsome stability
and had enhanced aqueous solubility due to incorporation of a more basic secondary amine.
EphB3 inhibitory activity was also demonstrated for representative analogs in cell culture and
a correlation with in vitro biochemical activity was demonstrated. Finally, 32 was profiled for
inhibitory activity against a panel of kinases and found to be quite selective for tyrosine kinases.
These studies provide useful molecular probes for examining the in vitro and cellular kinase-
dependent function of EphB3. Continued optimization of this compound series to further
increase selectivity could afford additional analogs useful for exploring the in vivo
pharmacology of EphB3 kinase inhibition in various animal disease models where EphB3
receptor expression occurs, either endogenously or as a result of injury or disease.
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Figure 1.
EphB3 inhibitor identified by HTS. Also shown is the numbering system for pyrazolo[1,5-a]
pyridines.
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Figure 2.
Inhibition assay of EphB3-induced autophosphorylation in HEK293 cells. D = DMSO, EB3
= ephrinB3, [Compound] = 10 µM, N = 3. Note: 32 was the oxylate salt.
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Scheme 1.
(Method A). Reagents and conditions: (a) (C=O)2Cl2, DCM, cat. DMF, 0 °C to rt, 2 h; (b)
R1R2NH, DCM, DIPEA, rt, 18 h; (c) LiAlH4, THF,Δ, 2 h.
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Scheme 2.
(Method B). (a) (PhO)2P(O)N3, THF, DIPEA, rt, 16 h; (b) BnOH, Δ, 12 h, 80% for two steps;
(c) H2 (1 atm), 10% Pd/C, MeOH/EtOAc (1:1), 45 min; (d) 2-Cl-PhC(O)Cl, DCM, DIPEA,
rt, 16 h, 36% over two steps.
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Scheme 3.
(Method C). (a) mesitylSO3NH2, DCM, 0 °C to rt, 30 min, 81%; (b) HC≡CCO2Me, K2CO3,
DMF, 50 °C, 72 h, 14%; (c) LiOH, MeOH/H2O, rt, 2 h, then 1N HCl, 85–90%; (d) SOCl2, 80
°C, 1 h; (e) 2-ClPhNH2, pyridine, rt, 16 h.
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Scheme 4.
(Method D). (a) HNR1R2, H2O, MW, 130 °C, 30 min, 90%; (b) 2,4-(NO2)2PhONH2,
CH3CN,Δ, 16 h, 81 %; (c) HC≡CC(O)NH-2-ClPh, K2CO3, DMF, 50 °C, 72 h.
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Scheme 5.
(Method E). (a) PhB(OH)2, Pd(PPh3)4, Na2CO3, CH3CN, H2O, 90 °C, 16 h, 98%; (b)
Piperidine, DMSO, n-Bu4NI, K2CO3, 95 °C, 16 h, 84%; (c) H2 (1 atm), 10% Pd/C, EtOH/
MeOH, rt, 16 h, 100%; (d) Me2NCH(OMe)2, toluene, Δ, 6 h then BrCH2C(O)NH-2-R-Ph
(where R = Cl or OMe), MeOH, Δ, 16 h, 17 – 45%; e) SO2Cl2, 0 °C to rt; f) 17, toluene,
NaHCO3, 120 °C, 3 d, 10%.
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Scheme 6.
(Method F). (a) 17, Pd(PPh3)4, Na2CO3, CH3CN, H2O, 90 °C, 6 h; (b) 10% Pd/C, H2 (1 atm),
EtOH, 16 h, 67% for two steps; (c) n-BuLi (2 equiv), (Me2SiClCH2)2, THF, − 78 °C, 1 h; (d)
n-BuLi (1 equiv), N-Boc-4-piperidone, − 78 °C to rt, 18 h, 58%; e) DMF-DMA, 85 °C, toluene
8 h, then BrCH2C(O)NH-2-Cl-Ph, MeOH, 85 °C, 18 h, 26 – 30%; f) 30% TFA in DCM, 1 h,
rt, 82%.
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Table 2
IC50 determinations for inhibiting EphB3 phosphorylation of BTK-peptide.
Cmpd R Method IC50 (µM)
60 3-indolyl a NA
61 N-methyl-3indolyl A NA
62 4-quinolinyl A NA
63 3-(1,2-benzisoxazolyl) C NA
64 3-(1H-indazolyl) Cb > 20
65 R1 C > 20
66 R2 Cb NA
67 R3 C ~ 15
68 R4 C NA
69 R5 Cb 0.46
a
Prepared by EDCI mediated coupling of indole-3-carboxylic acid with 2-chloroaniline
b
Method C, steps d and e; NA: Not active at 20µM.
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Table 4
Mouse liver microsome stability half-life and clearance values.
Compound t1/2 (min) CLint (µL/min/mg protein)
1 5.3 261 ± 18
32a 348 4 ± 1.4
54 27 51 ± 2.1
58 8.3 167 ± 4.2
69 3.8 361 ± 64
70 53 26 ± 0.80
71 20 71 ± 2.0
a
oxylate salt
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